Effects of weight loss on body composition and muscle mass Fat hiding inside your muscle is a stealth health risk: Every 1% increase in muscle fat content (myosteatosis) is linked to a 7% higher risk of cardiovascular disease, independent of overall body fat
Please note that deals can expire, and all prices are subject to change
According to the available timelines, the phase 3 clinical trial is expected to conclude in early 2026 with potential FDA approval in 2027
Retatrutide is often called "GLP-3" in online communities because it targets three receptors: GLP-1, GIP, and Glucagon
Interestingly, when data is studied in more detail, reported calorie intake remains adequate and in line with recommendations for GLP-1 RA users
Let's compare their chemical makeup and mechanism of action